Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pegloxenatide - Jiangsu Hengrui Medicine Co. / Jiangsu Hansoh Pharmaceutical

Next Previous
Drug Profile

Pegloxenatide - Jiangsu Hengrui Medicine Co. / Jiangsu Hansoh Pharmaceutical

Alternative Names: Fulaimei; PEG loxenatide; PEG-Loxenatide; PEX-168; Polyethylene glycol loxenatide

Latest Information Update: 18 Sep 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Jiangsu Hansoh Pharmaceutical; Jiangsu Hengrui Medicine Co.
  • Class Amines; Antihyperglycaemics; Obesity therapies; Peptides; Polyethylene glycols
  • Mechanism of Action Glucagon-like peptide-1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • Clinical Phase Unknown Diabetic nephropathies

Most Recent Events

  • 22 Jul 2024 Efficacy and adverse events data from a Clinical trial in Diabetic nephropathies released by Hansoh Pharma
  • 28 Oct 2019 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in China (SC, Injection)
  • 16 Sep 2019 Pharmacokinetics and adverse event data from a phase I trial in Type-2 diabetes mellitus presented at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD-2019)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top